Davis PL - Search Results

1

Relationship between p21 expression and mutation of the p53 tumor suppressor gene in normal and malignant ovarian epithelial cells.

Elbendary AA, Cirisano FD, Evans AC Jr, Davis PL, Iglehart JD, Marks JR, Berchuck A. Elbendary AA, et al. Among authors: davis pl. Clin Cancer Res. 1996 Sep;2(9):1571-5. Clin Cancer Res. 1996. PMID: 9816335

2

BRCA1 expression is induced before DNA synthesis in both normal and tumor-derived breast cells.

Vaughn JP, Davis PL, Jarboe MD, Huper G, Evans AC, Wiseman RW, Berchuck A, Iglehart JD, Futreal PA, Marks JR. Vaughn JP, et al. Among authors: davis pl. Cell Growth Differ. 1996 Jun;7(6):711-5. Cell Growth Differ. 1996. PMID: 8780884

3

Transforming growth factor beta 1 can induce CIP1/WAF1 expression independent of the p53 pathway in ovarian cancer cells.

Elbendary A, Berchuck A, Davis P, Havrilesky L, Bast RC Jr, Iglehart JD, Marks JR. Elbendary A, et al. Cell Growth Differ. 1994 Dec;5(12):1301-7. Cell Growth Differ. 1994. PMID: 7696178

4

Dominance of wild-type p53-mediated transcriptional activation in breast epithelial cells.

Davis P, Bazar K, Huper G, Lozano G, Marks J, Iglehart JD. Davis P, et al. Oncogene. 1996 Sep 19;13(6):1315-22. Oncogene. 1996. PMID: 8808706

5

BRCA1 expression is not directly responsive to estrogen.

Marks JR, Huper G, Vaughn JP, Davis PL, Norris J, McDonnell DP, Wiseman RW, Futreal PA, Iglehart JD. Marks JR, et al. Among authors: davis pl. Oncogene. 1997 Jan 9;14(1):115-21. doi: 10.1038/sj.onc.1200808. Oncogene. 1997. PMID: 9010238

6

Complex response of breast epithelial cell lines to topoisomerase inhibitors.

Davis PL, Shaiu WL, Scott GL, Iglehart JD, Hsieh TS, Marks JR. Davis PL, et al. Anticancer Res. 1998 Jul-Aug;18(4C):2919-32. Anticancer Res. 1998. PMID: 9713486

7

Isolation and initial characterization of the BRCA2 promoter.

Davis PL, Miron A, Andersen LM, Iglehart JD, Marks JR. Davis PL, et al. Oncogene. 1999 Oct 28;18(44):6000-12. doi: 10.1038/sj.onc.1202990. Oncogene. 1999. PMID: 10557089

8

Antisense DNA downregulation of the ERBB2 oncogene measured by a flow cytometric assay.

Vaughn JP, Iglehart JD, Demirdji S, Davis P, Babiss LE, Caruthers MH, Marks JR. Vaughn JP, et al. Proc Natl Acad Sci U S A. 1995 Aug 29;92(18):8338-42. doi: 10.1073/pnas.92.18.8338. Proc Natl Acad Sci U S A. 1995. PMID: 7667291 Free PMC article.

9

Phase I evaluation of prolonged-infusion gemcitabine with irinotecan for relapsed or refractory leukemia or lymphoma.

Bass AJ, Gockerman JP, Hammett E, DeCastro CM, Adams DJ, Rosner GL, Payne N, Davis P, Foster T, Moore JO, Rizzieri DA. Bass AJ, et al. J Clin Oncol. 2002 Jul 1;20(13):2995-3000. doi: 10.1200/JCO.2002.08.166. J Clin Oncol. 2002. PMID: 12089230 Clinical Trial.

10

Phase I evaluation of prolonged-infusion gemcitabine with mitoxantrone for relapsed or refractory acute leukemia.

Rizzieri DA, Bass AJ, Rosner GL, Gockerman JP, DeCastro CM, Petros WP, Adams DJ, Laughlin MJ, Davis P, Foster T, Jacobson R, Hurwitz H, Moore JO. Rizzieri DA, et al. J Clin Oncol. 2002 Feb 1;20(3):674-9. doi: 10.1200/JCO.2002.20.3.674. J Clin Oncol. 2002. PMID: 11821447 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

158 results

Search Page

Filters